Preliminary results of authentic recombinant somatropin treatment in human growth hormone deficient children. French Collaborative Study.
A total of 50 children with hGH deficiency have been enrolled in a multicentre open trial of recombinant somatropin in France. Recombinant somatropin, 0.2 IU/kg s.c., was administered 3 times/week (0.6 IU/kg/week). Results are available after 3 months' treatment for 24 of the patients (11 prepubertal, 13 pubertal). The mean growth rate increased from 3.8 +/- 1.5 cm/year to 9.9 +/- 3.6 cm/year. Only one child developed anti-hGH antibodies with a very low binding capacity of 0.02 mg/litre; adverse events were uncommon and probably unrelated to treatment.
Rappaport
R
R
D000293:Adolescent; D000906:Antibodies / Q000032:analysis; D001827:Body Height; D002648:Child; D002986:Clinical Trials as Topic; D005260:Female; D005602:France; D013006:Growth Hormone / Q000172:deficiency / Q000276:immunology / Q000627:therapeutic use*; D006801:Humans; D008297:Male; D011994:Recombinant Proteins / Q000276:immunology / Q000627:therapeutic use*
D000906:Antibodies; D011994:Recombinant Proteins; D013006:Growth Hormone